SGLT2 inhibitor versus DPP-4 inhibitor on left ventricular ejection fraction measuredby echocardiography in diabetic patients with acute myocardial infarction and midranged ejection fraction (EMPA-MI-MREF)

Chonnam National University Hospital0 个研究点目标入组 600 人开始时间: 待定最近更新: 2022年9月20日

适应症

试验速览

暂无简介。

•1) 19 years of age or older
•2) Left ventricular ejection fraction of 40~49% in echocardiography performed within 30 days of diagnosis of acute myocardial infarction
•3) Those diagnosed with type 2 diabetes and covered by SGLT2 inhibitor and DPP4 inhibitor insurance -> If metformin is stably administered for at least 12 weeks before participating in the trial and the HbA1c is 7.0% or higher, or If you are taking the second diabetes drug (Metformin + [sulfonylurea, Meglitinide, alpha-glucodase inhibitor, Thiazolidinedione, DPP4 inhibitor])
•4) When consent to participate in clinical trial

•1) Patients with hypersensitivity to SGLT-2 inhibitors
•2) Patients taking SGLT-2 inhibitors continuously
•3) Patients with type 1 diabetes or those who need insulin supply
•4) glomerular filtration rate (eGFR) <45 mL/min/1.73m 2 (MDRD formula), patients with end stage renal disease (ESRD) or patients on dialysis
•5) Patients with severe liver dysfunction including cirrhosis patients (hepatic enzyme levels more than 3 times the upper limit of normal)
•6) Patients who are taking drugs that can significantly affect blood sugar control (such as systemic corticosteroids) or are expected to take them during the trial period
•7) Women of childbearing potential who has a plan to become pregnant during clinical trials, or do not intend to use appropriate contraceptive methods
•8) Subjects who visited the hospital for cardiac arrest or cardiogenic shock before randomization, and whose survival is judged to be low.
•9) Persons diagnosed with heart failure before randomization
•10) You are participating in another randomized controlled study, or you are participating in an observational study that may affect the study.
•11) Those whose remaining life expectancy is less than 1 year or who are expected to have low adherence to treatment
•12) Those who are judged by other investigators to be inappropriate to participate in clinical trials.

发起方